What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
about
Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in LeishmaniaDifferences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discoveryVaccines for the leishmaniases: proposals for a research agendaT-cell expression cloning of Porphyromonas gingivalis genes coding for T helper-biased immune responses during infectionBabassu aqueous extract (BAE) as an adjuvant for T helper (Th)1-dependent immune responses in mice of a Th2 immune response-prone strain.Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c MiceLeishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).Th1 biased response to a novel Porphyromonas gingivalis protein aggravates bone resorption caused by this oral pathogenHistopathological and immunohistochemical aspects of American cutaneous leishmaniasis before and after different treatments.Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania majorIdentification of immunodominant Leishmania major antigenic markers of the early C57BL/6 and BALB/c mice infection stages.American cutaneous leishmaniasis in infancy and childhood.The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccineInduction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major.Cytokine expression in dogs with natural Leishmania infantum infection
P2860
Q26777203-DE47299C-B53C-4DCD-972E-B4C1BCBAB4C7Q28077110-2F2A7A3D-0829-4D78-89E4-721AE13C44EFQ28741577-E088474F-2F59-4AD8-A762-ADF7D69016F1Q33247526-D2C3AB65-3B1A-475D-8679-A3A169C52C78Q33806434-EA9D5561-1D28-4EBF-B6D8-8148D5BF9E6DQ35587034-84310AC0-D6B7-4E85-8E5F-54AC7486BA1CQ36680084-8D274B40-E36E-4436-A422-C297E50C2837Q36713642-E68DA33B-C8ED-465C-B1D5-9DDA11D0F26BQ36977741-80718649-A8F0-48DF-AB20-951FEEB7D990Q37053209-DE3B1F85-3182-434D-986F-EDEFCEF90A8FQ38971667-CC323F07-40A1-44F2-A011-C0EED8DEE839Q39336818-27DF7BE4-B0AE-49D7-A4EA-61D473799D98Q41278156-F6C14935-ED3F-413E-9BD4-EA41DB46458AQ52659333-41942A22-5E52-4A61-9895-51EFF4651B21Q56958576-00D3BB81-F2CC-4C49-9E47-C6998142492D
P2860
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@ast
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@en
type
label
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@ast
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@en
prefLabel
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@ast
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@en
P2860
P1476
What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
@en
P2093
A Campos-Neto
P2860
P304
P356
10.1590/S0100-879X2005000700001
P407
P577
2005-07-04T00:00:00Z